In a 70‑year‑old patient with transthyretin cardiac amyloidosis, atrial fibrillation, and left‑atrial sludge after cardioversion while on rivaroxaban, what is the appropriate next step after switching to dabigatran 120 mg twice daily?

Continue Dabigatran 120 mg Twice Daily and Perform Repeat TEE Before Any Future Cardioversion Attempts

In this 70-year-old patient with transthyretin cardiac amyloidosis, atrial fibrillation, and left atrial sludge discovered after cardioversion on rivaroxaban, the appropriate next step is to continue dabigatran 120 mg twice daily for long-term anticoagulation and mandate transesophageal echocardiography (TEE) before any future cardioversion attempts, regardless of anticoagulation duration or AF duration.

Rationale for Anticoagulation Strategy

The presence of left atrial sludge after cardioversion while on therapeutic anticoagulation is a critical finding that fundamentally changes this patient's management. This represents a failed anticoagulation strategy despite adequate therapy, which is particularly concerning in cardiac amyloidosis.

Why Dabigatran 120 mg is Appropriate

The FDA-approved dosing for dabigatran in atrial fibrillation is 1:

• 150 mg twice daily for CrCl >30 mL/min
• 75 mg twice daily for CrCl 15-30 mL/min

The 120 mg twice daily dose is NOT FDA-approved for atrial fibrillation in the United States 1. However, if this patient has CrCl 30-50 mL/min AND is taking a P-gp inhibitor, dose reduction may be warranted. The prescriber likely chose this dose based on:

• Renal function considerations
• Bleeding risk in cardiac amyloidosis
• Age >80 years (though this patient is 70)

If the patient has CrCl >30 mL/min without P-gp inhibitors, the dose should be increased to 150 mg twice daily 1. If CrCl is 15-30 mL/min, the dose should be decreased to 75 mg twice daily 1.

Critical Management Points for Cardiac Amyloidosis

Exceptionally High Thrombotic Risk

Patients with cardiac amyloidosis have dramatically elevated thromboembolic risk that exceeds standard CHA₂DS₂-VASc predictions:

• Anticoagulation is mandatory regardless of CHA₂DS₂-VASc score 2
• Left atrial thrombus occurs even with therapeutic anticoagulation 2, 3
• Left atrial thrombus occurs even in sinus rhythm 2
• In one study, 20.5% of ATTR-CM patients had definitive or suspected left atrial thrombus at time of planned cardioversion, with 5 patients having received adequate anticoagulation for >3 weeks 3

TEE is Mandatory Before Cardioversion

Standard guidelines recommend TEE before cardioversion when AF duration is ≥48 hours or unknown without 3 weeks of therapeutic anticoagulation 4, 5. However, in cardiac amyloidosis:

• TEE should be performed before cardioversion regardless of:
  • Duration of AF 2
  • Duration of therapeutic anticoagulation 2
  • Whether patient is in sinus rhythm 2

This patient's left atrial sludge demonstrates exactly why this recommendation exists—therapeutic anticoagulation failed to prevent thrombus formation.

Post-Cardioversion Anticoagulation Duration

Following cardioversion, guidelines universally recommend 4, 5:

• Minimum 4 weeks of therapeutic anticoagulation after successful cardioversion
• Long-term anticoagulation based on thromboembolic risk factors, NOT on maintenance of sinus rhythm

In this patient with cardiac amyloidosis, anticoagulation must continue indefinitely 2, as the thrombotic risk is intrinsic to the disease process, not just the AF.

Choice Between Warfarin and DOACs

There is no evidence favoring warfarin over DOACs in cardiac amyloidosis 2, 6. A retrospective study of 217 ATTR-CA patients with AF showed no difference in thrombotic events or major bleeding between warfarin and NOACs over 2.4 years of follow-up 6.

DOACs are preferred because 2:

• Ease of administration
• Lower intracranial hemorrhage risk (demonstrated in other cardiovascular populations)
• No need for INR monitoring

The switch from rivaroxaban to dabigatran is reasonable, though there is no evidence that one DOAC is superior to another in this population.

Rhythm Control Considerations

Poor Long-Term Success Rates

Rhythm control in cardiac amyloidosis is challenging 2, 3, 7:

• Immediate cardioversion success: 92.3% 3
• 3-month sinus rhythm maintenance: only 62.8% 3
• Diffuse atrial amyloid deposition creates poor substrate for rhythm maintenance 2

Rate Control Challenges

Traditional rate-controlling medications are poorly tolerated 2:

• Negative inotropes worsen restrictive physiology
• Amiodarone may be the best-tolerated agent 2
• Beta-blockers and calcium channel blockers often cause hypotension

Specific Management Algorithm

1. Verify renal function and adjust dabigatran dose accordingly:

   • CrCl >30 mL/min without P-gp inhibitors → 150 mg twice daily 1
   • CrCl 15-30 mL/min → 75 mg twice daily 1
   • Current 120 mg dose only appropriate if specific contraindications exist

2. Continue anticoagulation indefinitely regardless of rhythm 2

3. If considering future cardioversion:

   • Perform TEE immediately before procedure 2
   • Do NOT rely on anticoagulation duration alone 2, 3
   • Accept that recurrence is likely (37.2% will fail by 3 months) 3

4. If left atrial thrombus persists:

   • Postpone cardioversion 4
   • Continue anticoagulation for 4-12 weeks 4
   • Consider heparin bridging if necessary 4
   • Repeat TEE to document resolution 4

5. Monitor for stroke: One stroke occurred 2 months post-cardioversion in the ATTR-CM cohort despite anticoagulation 3

Common Pitfalls to Avoid

• Do not use CHA₂DS₂-VASc score to guide anticoagulation decisions in cardiac amyloidosis—anticoagulate all patients 2
• Do not skip TEE before cardioversion even with documented therapeutic anticoagulation 2, 3
• Do not discontinue anticoagulation after successful cardioversion 4, 2
• Do not assume standard DOAC dosing is appropriate—verify renal function and adjust accordingly 1
• Do not expect durable rhythm control—prepare patient for likely AF recurrence 3, 7